Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1 as a minor internal update with no user-facing content or functionality changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoChange DetectedPage revision updated to v3.4.1 with new dates (2026-02-04, 2026-01-15, 2026-01) and removal of 2025-12 entries.SummaryDifference0.1%

- Check31 days agoChange DetectedAdded: a glossary toggle and metadata fields including 'Last Update Submitted that Met QC Criteria' and 'Last Update Posted', plus the Revision: v3.4.0. Removed: the field 'Last Update Submitted that met QC Criteria', 'Last Update Posted (Estimated)', 'No FEAR Act data', and the previous revision 'v3.3.4'.SummaryDifference0.1%

- Check38 days agoChange DetectedFooter revision text updated to show Revision: v3.3.4, replacing the old Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange Detected- The page shows additions and deletions of date strings (e.g., 2025-12-23, 2025-12-04, 2025-12 and 2025-11-13, 2025-11-06, 2025-11), which appear to be update timestamps rather than alterations to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded a new Locations section with an expanded list of study sites (Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan, Minnesota, Missouri, New Jersey, Oregon, Pennsylvania, Tennessee, Texas, Virginia, Ontario, Quebec) and updated to Revision: v3.3.3; removed the prior per-state location subsections such as 'Arizona Locations' and 'California Locations'.SummaryDifference0.6%

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.